Guided Therapeutics (GTHP) Common Equity (2016 - 2025)
Historic Common Equity for Guided Therapeutics (GTHP) over the last 16 years, with Q3 2025 value amounting to -$5.7 million.
- Guided Therapeutics' Common Equity fell 1590.08% to -$5.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.7 million, marking a year-over-year decrease of 1590.08%. This contributed to the annual value of -$4.9 million for FY2024, which is 2845.51% down from last year.
- As of Q3 2025, Guided Therapeutics' Common Equity stood at -$5.7 million, which was down 1590.08% from -$5.5 million recorded in Q2 2025.
- In the past 5 years, Guided Therapeutics' Common Equity ranged from a high of -$4012.0 in Q1 2024 and a low of -$7.9 million during Q1 2021
- In the last 5 years, Guided Therapeutics' Common Equity had a median value of -$4.9 million in 2024 and averaged -$4.2 million.
- Over the last 5 years, Guided Therapeutics' Common Equity had its largest YoY gain of 9985.95% in 2024, and its largest YoY loss of 4078.43% in 2024.
- Quarter analysis of 5 years shows Guided Therapeutics' Common Equity stood at -$5.4 million in 2021, then soared by 47.05% to -$2.9 million in 2022, then crashed by 32.02% to -$3.8 million in 2023, then decreased by 28.46% to -$4.9 million in 2024, then dropped by 16.59% to -$5.7 million in 2025.
- Its Common Equity was -$5.7 million in Q3 2025, compared to -$5.5 million in Q2 2025 and -$5028.0 in Q1 2025.